Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach

Ch Tschuor, K. P. Croome, G. Sergeant, V. Cano, E. Schadde, V. Ardiles, K. Slankamenac, R. S. Clariá, E. De Santibaňes, R. Hernandez-Alejandro, P. A. Clavien

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background Portal vein ligation (PVL) or embolization (PVE) are standard approaches to induce liver hypertrophy of the future liver remnant (FLR) prior to hepatectomy in primarily non-resectable liver tumors. However, this approach fails in about one third of patients. Recently, the new "ALPPS" approach has been described that combines PVL with parenchymal transection to induce rapid liver hypertrophy. This series explores whether isolated parenchymal transection boosts liver hypertrophy in scenarios of failed PVL/PVE. Methods A multicenter database with 170 patients undergoing portal vein manipulation to increase the size of the FLR was screened for patients undergoing isolated parenchymal transection as a salvage procedure. Three patients who underwent PVL/PVE with subsequent insufficient volume gain and subsequently underwent parenchymal liver transection as a salvage procedure were identified. Patient characteristics, volume increase, postoperative complications and outcomes were analyzed. Results The first patient underwent liver transection 16 weeks after failed PVL with a standardized FLR (sFLR) of 30%, which increased to 47% in 7 days. The second patient showed a sFLR of 25% 28 weeks after PVL and subsequent PVE of segment IV, which increased to 41% in 7 days after transection. The third patient underwent liver partition 8 weeks after PVE with a sFLR of 19%, which increased to 37% in six days. All patients underwent a R0 resection. Conclusion Failed PVE or PVL appears to represent a good indication for the isolated parenchymal liver transection according to the newly developed ALPPS approach.

Original languageEnglish (US)
Pages (from-to)1230-1235
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume39
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Portal Vein
Liver
Ligation
Hypertrophy
Hepatectomy
Databases

Keywords

  • ALPPS
  • Hepatectomy
  • Liver neoplasms
  • Liver regeneration
  • Liver transaction
  • Salvage

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach. / Tschuor, Ch; Croome, K. P.; Sergeant, G.; Cano, V.; Schadde, E.; Ardiles, V.; Slankamenac, K.; Clariá, R. S.; De Santibaňes, E.; Hernandez-Alejandro, R.; Clavien, P. A.

In: European Journal of Surgical Oncology, Vol. 39, No. 11, 11.2013, p. 1230-1235.

Research output: Contribution to journalArticle

Tschuor, C, Croome, KP, Sergeant, G, Cano, V, Schadde, E, Ardiles, V, Slankamenac, K, Clariá, RS, De Santibaňes, E, Hernandez-Alejandro, R & Clavien, PA 2013, 'Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach', European Journal of Surgical Oncology, vol. 39, no. 11, pp. 1230-1235. https://doi.org/10.1016/j.ejso.2013.08.009
Tschuor, Ch ; Croome, K. P. ; Sergeant, G. ; Cano, V. ; Schadde, E. ; Ardiles, V. ; Slankamenac, K. ; Clariá, R. S. ; De Santibaňes, E. ; Hernandez-Alejandro, R. ; Clavien, P. A. / Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach. In: European Journal of Surgical Oncology. 2013 ; Vol. 39, No. 11. pp. 1230-1235.
@article{c576af4979a74ce79b18e27ff3d124f4,
title = "Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach",
abstract = "Background Portal vein ligation (PVL) or embolization (PVE) are standard approaches to induce liver hypertrophy of the future liver remnant (FLR) prior to hepatectomy in primarily non-resectable liver tumors. However, this approach fails in about one third of patients. Recently, the new {"}ALPPS{"} approach has been described that combines PVL with parenchymal transection to induce rapid liver hypertrophy. This series explores whether isolated parenchymal transection boosts liver hypertrophy in scenarios of failed PVL/PVE. Methods A multicenter database with 170 patients undergoing portal vein manipulation to increase the size of the FLR was screened for patients undergoing isolated parenchymal transection as a salvage procedure. Three patients who underwent PVL/PVE with subsequent insufficient volume gain and subsequently underwent parenchymal liver transection as a salvage procedure were identified. Patient characteristics, volume increase, postoperative complications and outcomes were analyzed. Results The first patient underwent liver transection 16 weeks after failed PVL with a standardized FLR (sFLR) of 30{\%}, which increased to 47{\%} in 7 days. The second patient showed a sFLR of 25{\%} 28 weeks after PVL and subsequent PVE of segment IV, which increased to 41{\%} in 7 days after transection. The third patient underwent liver partition 8 weeks after PVE with a sFLR of 19{\%}, which increased to 37{\%} in six days. All patients underwent a R0 resection. Conclusion Failed PVE or PVL appears to represent a good indication for the isolated parenchymal liver transection according to the newly developed ALPPS approach.",
keywords = "ALPPS, Hepatectomy, Liver neoplasms, Liver regeneration, Liver transaction, Salvage",
author = "Ch Tschuor and Croome, {K. P.} and G. Sergeant and V. Cano and E. Schadde and V. Ardiles and K. Slankamenac and Clari{\'a}, {R. S.} and {De Santibaňes}, E. and R. Hernandez-Alejandro and Clavien, {P. A.}",
year = "2013",
month = "11",
doi = "10.1016/j.ejso.2013.08.009",
language = "English (US)",
volume = "39",
pages = "1230--1235",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion - An extension of the ALPPS approach

AU - Tschuor, Ch

AU - Croome, K. P.

AU - Sergeant, G.

AU - Cano, V.

AU - Schadde, E.

AU - Ardiles, V.

AU - Slankamenac, K.

AU - Clariá, R. S.

AU - De Santibaňes, E.

AU - Hernandez-Alejandro, R.

AU - Clavien, P. A.

PY - 2013/11

Y1 - 2013/11

N2 - Background Portal vein ligation (PVL) or embolization (PVE) are standard approaches to induce liver hypertrophy of the future liver remnant (FLR) prior to hepatectomy in primarily non-resectable liver tumors. However, this approach fails in about one third of patients. Recently, the new "ALPPS" approach has been described that combines PVL with parenchymal transection to induce rapid liver hypertrophy. This series explores whether isolated parenchymal transection boosts liver hypertrophy in scenarios of failed PVL/PVE. Methods A multicenter database with 170 patients undergoing portal vein manipulation to increase the size of the FLR was screened for patients undergoing isolated parenchymal transection as a salvage procedure. Three patients who underwent PVL/PVE with subsequent insufficient volume gain and subsequently underwent parenchymal liver transection as a salvage procedure were identified. Patient characteristics, volume increase, postoperative complications and outcomes were analyzed. Results The first patient underwent liver transection 16 weeks after failed PVL with a standardized FLR (sFLR) of 30%, which increased to 47% in 7 days. The second patient showed a sFLR of 25% 28 weeks after PVL and subsequent PVE of segment IV, which increased to 41% in 7 days after transection. The third patient underwent liver partition 8 weeks after PVE with a sFLR of 19%, which increased to 37% in six days. All patients underwent a R0 resection. Conclusion Failed PVE or PVL appears to represent a good indication for the isolated parenchymal liver transection according to the newly developed ALPPS approach.

AB - Background Portal vein ligation (PVL) or embolization (PVE) are standard approaches to induce liver hypertrophy of the future liver remnant (FLR) prior to hepatectomy in primarily non-resectable liver tumors. However, this approach fails in about one third of patients. Recently, the new "ALPPS" approach has been described that combines PVL with parenchymal transection to induce rapid liver hypertrophy. This series explores whether isolated parenchymal transection boosts liver hypertrophy in scenarios of failed PVL/PVE. Methods A multicenter database with 170 patients undergoing portal vein manipulation to increase the size of the FLR was screened for patients undergoing isolated parenchymal transection as a salvage procedure. Three patients who underwent PVL/PVE with subsequent insufficient volume gain and subsequently underwent parenchymal liver transection as a salvage procedure were identified. Patient characteristics, volume increase, postoperative complications and outcomes were analyzed. Results The first patient underwent liver transection 16 weeks after failed PVL with a standardized FLR (sFLR) of 30%, which increased to 47% in 7 days. The second patient showed a sFLR of 25% 28 weeks after PVL and subsequent PVE of segment IV, which increased to 41% in 7 days after transection. The third patient underwent liver partition 8 weeks after PVE with a sFLR of 19%, which increased to 37% in six days. All patients underwent a R0 resection. Conclusion Failed PVE or PVL appears to represent a good indication for the isolated parenchymal liver transection according to the newly developed ALPPS approach.

KW - ALPPS

KW - Hepatectomy

KW - Liver neoplasms

KW - Liver regeneration

KW - Liver transaction

KW - Salvage

UR - http://www.scopus.com/inward/record.url?scp=84885431395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885431395&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2013.08.009

DO - 10.1016/j.ejso.2013.08.009

M3 - Article

C2 - 23994139

AN - SCOPUS:84885431395

VL - 39

SP - 1230

EP - 1235

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 11

ER -